61 related articles for article (PubMed ID: 38632504)
1. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.
Meehan TF; Conte N; Goldstein T; Inghirami G; Murakami MA; Brabetz S; Gu Z; Wiser JA; Dunn P; Begley DA; Krupke DM; Bertotti A; Bruna A; Brush MH; Byrne AT; Caldas C; Christie AL; Clark DA; Dowst H; Dry JR; Doroshow JH; Duchamp O; Evrard YA; Ferretti S; Frese KK; Goodwin NC; Greenawalt D; Haendel MA; Hermans E; Houghton PJ; Jonkers J; Kemper K; Khor TO; Lewis MT; Lloyd KCK; Mason J; Medico E; Neuhauser SB; Olson JM; Peeper DS; Rueda OM; Seong JK; Trusolino L; Vinolo E; Wechsler-Reya RJ; Weinstock DM; Welm A; Weroha SJ; Amant F; Pfister SM; Kool M; Parkinson H; Butte AJ; Bult CJ
Cancer Res; 2017 Nov; 77(21):e62-e66. PubMed ID: 29092942
[TBL] [Abstract][Full Text] [Related]
2. Generation and application of patient-derived xenograft models in pancreatic cancer research.
Wang CF; Shi XJ
Chin Med J (Engl); 2019 Nov; 132(22):2729-2736. PubMed ID: 31725451
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived xenograft models of BRCA-associated pancreatic cancers.
Golan T; Atias D; Stossel C; Raitses-Gurevich M
Adv Drug Deliv Rev; 2021 Apr; 171():257-265. PubMed ID: 33617901
[TBL] [Abstract][Full Text] [Related]
4. Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor.
Wen S; Lin X; Luo W; Pan Y; Liao F; Wang Z; Zhan B; Feng J; Huang H
BMC Cancer; 2024 Apr; 24(1):485. PubMed ID: 38632504
[TBL] [Abstract][Full Text] [Related]
5. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer.
Guo S; Gao S; Liu R; Shen J; Shi X; Bai S; Wang H; Zheng K; Shao Z; Liang C; Peng S; Jin G
FASEB J; 2019 Jan; 33(1):873-884. PubMed ID: 30091943
[TBL] [Abstract][Full Text] [Related]
6. Optimal Organ for Patient-derived Xenograft Model in Pancreatic Cancer and Microenvironment that Contributes to Success.
Eguchi S; Kimura K; Kageyama K; Tani N; Tanaka R; Nishio K; Shinkawa H; Ohira GO; Amano R; Tanaka S; Yamamoto A; Takemura S; Yashiro M; Kubo S
Anticancer Res; 2022 May; 42(5):2395-2404. PubMed ID: 35489770
[TBL] [Abstract][Full Text] [Related]
7. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma.
Liu Z; Ahn MH; Kurokawa T; Ly A; Zhang G; Wang F; Yamada T; Sadagopan A; Cheng J; Ferrone CR; Liss AS; Honselmann KC; Wojtkiewicz GR; Ferrone S; Wang X
J Transl Med; 2020 Jun; 18(1):255. PubMed ID: 32580742
[TBL] [Abstract][Full Text] [Related]
8. Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer.
Dutta P; Perez MR; Lee J; Kang Y; Pratt M; Salzillo TC; Weygand J; Zacharias NM; Gammon ST; Koay EJ; Kim M; McAllister F; Sen S; Maitra A; Piwnica-Worms D; Fleming JB; Bhattacharya PK
J Proteome Res; 2019 Jul; 18(7):2826-2834. PubMed ID: 31120258
[TBL] [Abstract][Full Text] [Related]
9. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival.
Pergolini I; Morales-Oyarvide V; Mino-Kenudson M; Honselmann KC; Rosenbaum MW; Nahar S; Kem M; Ferrone CR; Lillemoe KD; Bardeesy N; Ryan DP; Thayer SP; Warshaw AL; Fernández-Del Castillo C; Liss AS
PLoS One; 2017; 12(8):e0182855. PubMed ID: 28854237
[TBL] [Abstract][Full Text] [Related]
10. KEGG for taxonomy-based analysis of pathways and genomes.
Kanehisa M; Furumichi M; Sato Y; Kawashima M; Ishiguro-Watanabe M
Nucleic Acids Res; 2023 Jan; 51(D1):D587-D592. PubMed ID: 36300620
[TBL] [Abstract][Full Text] [Related]
11. Metabolic analysis as a driver for discovery, diagnosis, and therapy.
DeBerardinis RJ; Keshari KR
Cell; 2022 Jul; 185(15):2678-2689. PubMed ID: 35839759
[TBL] [Abstract][Full Text] [Related]
12. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights.
Pang Z; Chong J; Zhou G; de Lima Morais DA; Chang L; Barrette M; Gauthier C; Jacques PÉ; Li S; Xia J
Nucleic Acids Res; 2021 Jul; 49(W1):W388-W396. PubMed ID: 34019663
[TBL] [Abstract][Full Text] [Related]
13. KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth.
Raho S; Capobianco L; Malivindi R; Vozza A; Piazzolla C; De Leonardis F; Gorgoglione R; Scarcia P; Pezzuto F; Agrimi G; Barile SN; Pisano I; Reshkin SJ; Greco MR; Cardone RA; Rago V; Li Y; Marobbio CMT; Sommergruber W; Riley CL; Lasorsa FM; Mills E; Vegliante MC; De Benedetto GE; Fratantonio D; Palmieri L; Dolce V; Fiermonte G
Nat Metab; 2020 Dec; 2(12):1373-1381. PubMed ID: 33230296
[TBL] [Abstract][Full Text] [Related]
14. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours.
Zhu Z; Achreja A; Meurs N; Animasahun O; Owen S; Mittal A; Parikh P; Lo TW; Franco-Barraza J; Shi J; Gunchick V; Sherman MH; Cukierman E; Pickering AM; Maitra A; Sahai V; Morgan MA; Nagrath S; Lawrence TS; Nagrath D
Nat Metab; 2020 Aug; 2(8):775-792. PubMed ID: 32694827
[TBL] [Abstract][Full Text] [Related]
15. Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth.
Lei MZ; Li XX; Zhang Y; Li JT; Zhang F; Wang YP; Yin M; Qu J; Lei QY
Signal Transduct Target Ther; 2020 May; 5(1):70. PubMed ID: 32467562
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
